XOMA is a biopharmaceutical corporation that specializes in antibody-based therapeutics and capabilities [24]. It is traded on the NASDAQ and its main competitors are Rexahn Pharmaceuticals Incorporated and Intellipharmaceutics International Incorporated The business currently appears to be at a peak low and close to the bottom of its 52-week price range. It is forecasted to start increasing dramatically over the next year, and so 7,500 shares were purchased at $1.55 apiece.